Y-mAbs Therapeutics, Inc. announced new interim data from the Phase 2 Trial 201 of naxitamab in combination with granulocyte-macrophage colony-stimulating factor in patients with relapsed or.
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Get Free Report) insider Thomas Gad sold 25,000 shares of the company’s stock in a transaction on Tuesday, May 21st. The stock was sold at an average price of $12.00, for a total value of $300,000.00. Following the completion of the sale, the insider now owns 240,032 shares of the […]
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Get Free Report) insider Thomas Gad sold 7,351 shares of the company’s stock in a transaction on Thursday, May 23rd. The stock was sold at an average price of $13.00, for a total value of $95,563.00. Following the transaction, the insider now owns 232,681 shares in the company, valued at […]
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Get Free Report) was up 7.5% during mid-day trading on Wednesday . The stock traded as high as $12.75 and last traded at $12.71. Approximately 31,560 shares were traded during trading, a decline of 92% from the average daily volume of 404,084 shares. The stock had previously closed at $11.82. […]